Anti-Human Claudin 18.2 (Zolbetuximab Biosimilar)
Catalog #500067
| Cat # | Size | Price | Quantity | |
|---|---|---|---|---|
| 500067 | 1 mg | $200.00 | ||
| 500067 | 5 mg | $600.00 | ||
| 500067 | 20 mg | $1,250.00 |
Product Details
Zolbetuximab biosimilar is a monoclonal antibody targeting Claudin-18.2 (CLDN18.2), a tight junction protein expressed in gastric and pancreatic cancers. It is being explored as a potential treatment for gastrointestinal adenocarcinomas and pancreatic tumors. The biosimilar is typically a recombinant human IgG1 monoclonal antibody produced in mammalian cells, ensuring high specificity and effectiveness in research applications.
Specifications
| Clone | Zolbetuximab |
|---|---|
| Reactivities | Human |
| Isotype | Human IgG1 |
| Recommended Isotype Control | Human IgG1 isotype control |
| Format | Liquid |
| Formluation | PBS, pH 7.4 |
| Sterility | 0.2 µm filtered |
| Clonality | Recombinant |
| Conjugation | Unconjugated |
| Immunogen | Human Claudin 18.2 |
| Host | CHO cells |
| Purity | >95% (HPLC, SDS-PAGE) |
| Endotoxin | < 1.0 EU/mg (LAL assay) |
| Grade | In vivo ready (RUO) |
| Application | Neutralization; Flow Cytometry; ELISA; WB |
| Purification | Protein A |
| Storage Conditions | 2-8 °C, Avoid freeze / thaw cycle |
| Shelf Life | 6 months |
| Regulatory Status | RUO |